Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors (Q35029533)

5 August 2017

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors (English)

1 reference

5 August 2017

Jun J Mao

1

1 reference

5 August 2017

H Irene Su

2

1 reference

5 August 2017

Rui Feng

3

1 reference

5 August 2017

Michelle L Donelson

4

1 reference

5 August 2017

Richard Aplenc

5

1 reference

5 August 2017

Timothy R Rebbeck

6

1 reference

5 August 2017

Frank Stanczyk

7

1 reference

5 August 2017

Angela DeMichele

8

1 reference

5 August 2017

20 January 2011

1 reference

5 August 2017

Breast Cancer Research

1 reference

5 August 2017

13

1 reference

5 August 2017

1

1 reference

5 August 2017

R8

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr2813

5 August 2017

0 references

cites work

Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Advantages and challenges of mass spectrometry assays for steroid hormones

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome

8 July 2018

1 reference

Musculoskeletal pain and menopausal status

21 January 2018

1 reference

Polymorphisms associated with circulating sex hormone levels in postmenopausal women

21 January 2018

1 reference

Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women

21 January 2018

1 reference

Tolerance of adjuvant letrozole outside of clinical trials

21 January 2018

1 reference

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women

21 January 2018

1 reference

Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery.

21 January 2018

1 reference

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

Human aromatase: gene resequencing and functional genomics

21 January 2018

1 reference

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

21 January 2018

1 reference

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

21 January 2018

1 reference

Aromatase inhibitors and arthralgia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3109575

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

25 October 2018

1 reference

Aromatase inhibitor-associated arthralgias

21 January 2018

1 reference

12 December 2020

A tetranucleotide repeat polymorphism inCYP19 and breast cancer risk

1 reference

12 December 2020

Participation in cancer clinical trials: race-, sex-, and age-based disparities

1 reference

12 December 2020

Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study

1 reference

12 December 2020

Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR2813

1 reference

Dimensions Publication ID

5 August 2017

0 references

0 references

1 reference

5 August 2017

1 reference